Professor David Taylor
Professor David Taylor
Maudsley Hospital
Verified email at
Cited by
Cited by
South London and Maudsley and Oxleas NHS Trusts Prescribing Guidelines
D Taylor, R Kerwin, C Paton
Taylor and Francis, London, 2005
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
RL Carhart-Harris, M Bolstridge, J Rucker, CMJ Day, D Erritzoe, M Kaelen, ...
The Lancet Psychiatry 3 (7), 619-627, 2016
Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology
GM Goodwin, PM Haddad, IN Ferrier, JK Aronson, TRH Barnes, ...
Journal of Psychopharmacology 30 (6), 495-553, 2016
Atypical antipsychotics and weightgain—a systematic review
DM Taylor, R McAskill
Acta Psychiatrica Scandinavica 101 (6), 416-432, 2000
Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines
A Cleare, CM Pariante, AH Young, IM Anderson, D Christmas, PJ Cowen, ...
Journal of Psychopharmacology 29 (5), 459-525, 2015
Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology
OD Howes, R McCutcheon, O Agid, A De Bartolomeis, NJM Van Beveren, ...
American Journal of Psychiatry 174 (3), 216-229, 2017
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
RL Carhart-Harris, M Bolstridge, CMJ Day, J Rucker, R Watts, DE Erritzoe, ...
Psychopharmacology 235 (2), 399-408, 2018
Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation
OD Howes, F Vergunst, S Gee, P McGuire, S Kapur, D Taylor
The British Journal of Psychiatry 201 (6), 481-485, 2012
Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis
D Baldwin, R Woods, R Lawson, D Taylor
Bmj 342, 2011
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
AH Barnett, P Mackin, I Chaudhry, A Farooqi, R Gadsby, A Heald, J Hill, ...
Journal of Psychopharmacology 21 (4), 357-373, 2007
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
S Brissos, MR Veguilla, D Taylor, V Balanzá-Martinez
Therapeutic advances in psychopharmacology 4 (5), 198-219, 2014
Antipsychotics and QT prolongation
DM Taylor
Acta Psychiatrica Scandinavica 107 (2), 85-95, 2003
Atypical antipsychotics and hyperglycaemia
S Mir, D Taylor
International clinical psychopharmacology 16 (2), 63-74, 2001
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies
D Taylor, A Sparshatt, S Varma, O Olofinjana
Bmj 348, 2014
Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?
RM Murray, D Quattrone, S Natesan, J van Os, M Nordentoft, O Howes, ...
The British Journal of Psychiatry 209 (5), 361-365, 2016
Psychiatrists’ attitude towards and knowledge of clozapine treatment
J Nielsen, M Dahm, H Lublin, D Taylor
Journal of Psychopharmacology, 2010
A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review
E Whiskey, U Werneke, D Taylor
International clinical psychopharmacology 16 (5), 239-252, 2001
A systematic review of the evidence of clozapine's anti-aggressive effects
C Frogley, D Taylor, G Dickens, M Picchioni
The The International Journal of Neuropsychopharmacology 15 (9), 1351-1371, 2012
Tolerability of atypical antipsychotics
C Stanniland, D Taylor
Drug safety 22 (3), 195-214, 2000
A UK audit of screening for the metabolic side effects of antipsychotics in community patients
TRE Barnes, C Paton, MR Cavanagh, E Hancock, DM Taylor, ...
Schizophrenia bulletin 33 (6), 1397-1403, 2007
The system can't perform the operation now. Try again later.
Articles 1–20